Acute Porphyria Drugs

Monograph

S01EC04 - Brinzolamide
Propably not porphyrinogenic
PNP

Rationale
sulfonamide derivative preferentially distributed to red blood cells. Probably insignificant hepatic load. Very long final elimination time from erythrocytes.
Chemical description
sulfonamide used in eyedrops (10 mg/mL) to reduce the intraocular pressure in glaucoma. Isopropyl ester prodrug to an active prostaglandine analogue. Conversion to the active acid form takes place through hydrolysis. Reaches circulation in topical application but due to effective bindnding to erytrocyte carboanhydrases the plasma levels are very low, often lower than 10 ng/ml. Long elimination time in blood; half time about six months. Metabolized by CYPs 3A4 (major enzyme), 2A6, 2C8, 2C9. Brinzolamide and its N-desethyl metabolite is excreted in urine, 20 % as metabolites.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
Similar drugs
Explore alternative drugs in similar therapeutic classes S01E / S01EC or go back.
References
Tradenames

Azopt · Brinzo-Vision · Brinzolamide · Brizadopt · Optilamid Azopt Azopt · Bolesin · Brinzolamida Azopt Azopt · Brinzaflux · Brinzolamide Azopt Azopt Azopt · Brinzolamide Azopt · Brinzolamid · Brinzolamide Azopt · Brinzolamid · Brinzolamide Azopt · Brinzolamide · Optilamid Azopt Azopt Azopt · Brinzolamide Azopt · Brinzolamide · Brizadopt · Optilamid Azopt · Brinzolamide Azopt · Brinzolamide · Brizadopt Azopt Azopt · Brinzolamid Azopt
In cooperation with IpNet
© NAPOS 2025
An unhandled error has occurred. Reload 🗙